Article | March 26, 2020

COVID-19 And Clinical Trial Regulatory Guidelines

Source: Greenphire

By Jim Murphy, CEO, Greenphire

Adaptive Trial Design and Implementation

Within the past week, both the FDA and EMA issued guidance with regards to the conduct of clinical trials during the COVID-19 pandemic.

This swift action taken by the regulatory agencies was in direct response to global concerns around assuring the safety of clinical trial participants, maintaining compliance with good clinical practice (GCP) and minimizing risks to trial integrity during this unprecedented time.

These latest regulatory guidelines permit sites, sponsors and CROs to adjust their study operations to meet changing conditions for ongoing trials, however there are conditions that must be met in order for new solutions to be considered.

Here are six steps the industry can take to support the needs of patients and sites.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: